Artesunate, a new antimalarial clinical drug, exhibits potent anti‐AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15986
Abstract: Artesunate, approved by the Food and Drug Administration in 2020 as a new treatment for severe malaria, also shows anti‐tumour activity against acute myeloid leukaemia (AML). However, the underlying molecular mechanism(s) of artesunate‐induced apoptosis and… read more here.
Keywords: antimalarial clinical; aml; artesunate new; activity ... See more keywords